NCT06136650 2026-04-15
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
17 trialsNCT06136624 2026-04-08
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06353386 2026-03-24
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06136598 2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06104449 2026-03-06
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04729114 2026-02-04
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Inc
Phase 1 Recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT01867710 2019-07-05
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Janssen Pharmaceutica N.V., Belgium
Phase 2 Completed
NCT00531284 2017-08-15
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
Phase 1/2 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT01188187 2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3 Completed
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00473512 2014-03-27
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
Cougar Biotechnology, Inc.
Phase 1/2 Completed